Jim Finnel
Fallen Cannabis Warrior & Ex News Moderator
Influence of Anandamide, the Endogenous Agonist of Cannabinoid Receptors on the Circulatory System
Authors:
Kwolek Grzegorz
Zakrzeska Agnieszka
Kozłowska Hanna
Malinowska Barbara
From: Zakład Fizjologii Doświadczalnej Akademii Medycznej, Białystok. gkwolek@amb.edu.pl
Postȩpy higieny i medycyny doświadczalnej (Online)
Publish Date: May 2005
ISSN: 1732-2693
Volume: 59
Issue:
Pages: 208-18
Medium: Internet
Language:
Citation (JAMA): Kwolek Grzegorz, Zakrzeska Agnieszka, Kozłowska Hanna, et al. Influence of Anandamide, the Endogenous Agonist of Cannabinoid Receptors on the Circulatory System. May 2005;59:208-18
Abstract
Cannabinoids, the active ingredients of Cannabis sativa, have been used by humans as hallucinogens and therapeutic agents for thousands of years. These agents are now known to act through the cannabinoid CB1 and CB2 receptors. The recent discovery of endogenous cannabinoids and the fact that they are involved in the pathology of hypotension associated with hemorrhage, sepsis, cirrhosis, and myocardial infarction indicate that cannabinoids play a greater role in human and animal pathophysiology than initially anticipated. Anandamide is the first of the endogenous cannabinoid ligands discovered. Its intravenous administration produces a characteristic three-phase response in the circulatory systems of experimental animals: In phase 1 — a short-lasting decrease in heart rate and systemic blood pressure is related to activation of vanilloid TRPV1 receptors. In phase 2 an increase in blood pressure involves multiple mechanisms, both central (probably through the rostral ventrolateral medulla) and peripheral (vascular, Ca2+-dependent). In phase 3 there is a prolonged decrease in blood pressure and sometimes bradycardia, related to the activation of cannabinoid CB1 and vanilloid TRPV1 receptors. On the basis of this three-phase mechanism, the present paper intends to describe the participation of anandamide in the circulatory system under physiological and pathophysiological conditions. It also discusses the possibility of applying cannabinoid ligands as new therapeutic agents for the treatment of some pathologies.
Mesh Headings (Keywords): Animals, Arachidonic Acids, Blood Circulation, Blood Pressure, Cardiovascular Physiology, Heart Rate, Hemodynamics, Humans, Polyunsaturated Alkamides, Receptors, Cannabinoid
Check for Full Text / PubMed Unique Identifier (PMID): 15928605
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.
Source: Influence of Anandamide, the Endogenous Agonist of Cannabinoid Receptors on the Circulatory System - Medical Journals - Healia
Authors:
Kwolek Grzegorz
Zakrzeska Agnieszka
Kozłowska Hanna
Malinowska Barbara
From: Zakład Fizjologii Doświadczalnej Akademii Medycznej, Białystok. gkwolek@amb.edu.pl
Postȩpy higieny i medycyny doświadczalnej (Online)
Publish Date: May 2005
ISSN: 1732-2693
Volume: 59
Issue:
Pages: 208-18
Medium: Internet
Language:
Citation (JAMA): Kwolek Grzegorz, Zakrzeska Agnieszka, Kozłowska Hanna, et al. Influence of Anandamide, the Endogenous Agonist of Cannabinoid Receptors on the Circulatory System. May 2005;59:208-18
Abstract
Cannabinoids, the active ingredients of Cannabis sativa, have been used by humans as hallucinogens and therapeutic agents for thousands of years. These agents are now known to act through the cannabinoid CB1 and CB2 receptors. The recent discovery of endogenous cannabinoids and the fact that they are involved in the pathology of hypotension associated with hemorrhage, sepsis, cirrhosis, and myocardial infarction indicate that cannabinoids play a greater role in human and animal pathophysiology than initially anticipated. Anandamide is the first of the endogenous cannabinoid ligands discovered. Its intravenous administration produces a characteristic three-phase response in the circulatory systems of experimental animals: In phase 1 — a short-lasting decrease in heart rate and systemic blood pressure is related to activation of vanilloid TRPV1 receptors. In phase 2 an increase in blood pressure involves multiple mechanisms, both central (probably through the rostral ventrolateral medulla) and peripheral (vascular, Ca2+-dependent). In phase 3 there is a prolonged decrease in blood pressure and sometimes bradycardia, related to the activation of cannabinoid CB1 and vanilloid TRPV1 receptors. On the basis of this three-phase mechanism, the present paper intends to describe the participation of anandamide in the circulatory system under physiological and pathophysiological conditions. It also discusses the possibility of applying cannabinoid ligands as new therapeutic agents for the treatment of some pathologies.
Mesh Headings (Keywords): Animals, Arachidonic Acids, Blood Circulation, Blood Pressure, Cardiovascular Physiology, Heart Rate, Hemodynamics, Humans, Polyunsaturated Alkamides, Receptors, Cannabinoid
Check for Full Text / PubMed Unique Identifier (PMID): 15928605
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.
Source: Influence of Anandamide, the Endogenous Agonist of Cannabinoid Receptors on the Circulatory System - Medical Journals - Healia
